Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.

@article{Brynne1999FluoxetineIT,
  title={Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.},
  author={N Brynne and C Svanstr{\"o}m and Anna {\AA}berg-Wistedt and Bengt Hall{\'e}n and Leif Bertilsson},
  journal={British journal of clinical pharmacology},
  year={1999},
  volume={48 4},
  pages={553-63}
}
AIMS To investigate the change in disposition of tolterodine during coadministration of the potent cytochrome P450 2D6 (CYP2D6) inhibitor fluoxetine. METHODS Thirteen patients received tolterodine l-tartrate 2 mg twice daily for 2.5 days, followed by fluoxetine 20 mg once daily for 3 weeks and then concomitant administration for an additional 2.5 days. They were characterized as extensive metabolizers (EM1 with one functional CYP2D6 gene, EM2 with two functional genes) or poor metabolizers… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…